Somatropin Disease InteractionsMean observation period was 3. Total number of patient-years was 20, Observed number of cases O was compared with expected number of cases E. Reference rates were from Sweden, three additional European regions, and one U. Somatropin diabetes mellitus incidence was somatropn. In subjects not developing diabetes, plasma glucose concentrations increased from
The role of growth hormone in diabetes mellitus. - PubMed - NCBI
Somatropin is contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin should be discontinued if there is any evidence of recurrence. Treatment with somatropin is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure.
Patients with these conditions have an increased risk of mortality. Somatropin is contraindicated in patients with active proliferative or severe non- proliferative diabetic retinopathy. Somatropin is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients. The use of growth hormone has been associated with resistance to insulin.
Patients with diabetes mellitus or impaired glucose tolerance should be observed closely during therapy. The use of growth hormone has been associated with the development of hypothyroidism. Patients should be monitored baseline and periodically for adequate thyroid function.
Inadequate treatment of hypothyroidism may inhibit the optimal response to growth hormone. Fundoscopic examination should be performed before treatment initiation to exclude preexisting papilledema, and should be continued periodically during treatment. If papilledema is observed during treatment, therapy should be stopped.
Treatment could be restarted at a lower dose once intracranial hypertension has been resolved. Patients with Turner Syndrome might be at increased risk of developing intracranial hypertension. Progression of scoliosis can occur in patients who experience rapid growth. Since somatropin increases growth rate, children with a history of scoliosis should be monitored for progression of this condition.
Physicians should be alert for this skeletal abnormality which can be commonly seen in patients with Turner and Prader-Willi syndromes, and can manifest during somatropin treatment. Somatropin may increase the risk of otitis media in patients with Turner syndrome.
These patients should be evaluated carefully for otitis media and other ear disorders as they have an increased risk of ear and hearing disorders. Do not stop taking any medications without consulting your healthcare provider. Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect.
In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof.
This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient.
Multum Information Services, Inc. Copyright Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.
Available for Android and iOS devices. Subscribe to receive email notifications whenever new articles are published. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. To view content sources and attributions, please refer to our editorial policy. We comply with the HONcode standard for trustworthy health information - verify here. Drug Interactions Disease Interactions 9.
Drug Interaction Classification The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. Minor Minimally clinically significant. Unknown No information available.
Somatropin Rating 20 User Reviews 7.